Lecithin: cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein which is responsible for the formation of cholesteryl ester in plasma. The carbohydrate content has been estimated to be approx. 250% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence. In the present study, we have examined which of these sites are utilized and how the N-glycosylation affects the secretion and function of the enzyme. Site-directed mutagenesis was performed to eliminate the glycosylation consensus sequence at each of the four potential sites, and the mutant proteins were expressed in COS cells. The amount of each mutant LCAT secreted was similar to that of the wild-type enzyme but the molecular mass was decreased by 3-4 kDa. The specific activity of each mutant LCAT was
INTRODUCTION
Lecithin: cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein enzyme responsible for the formation of cholesteryl ester in plasma via transfer of the sn-2 fatty acid from phosphatidylcholine to the 3-hydroxy group of cholesterol in plasma [1] . This enzyme is synthesized in hepatocytes and secreted into the blood where it primarily acts on high-density lipoprotein [2] . Full activity appears to require apolipoprotein A-I (apo A-I) which is also the major structural protein ofhigh-density lipoprotein [3, 4] . In plasma, LCAT protein has an apparent molecular mass of about 63-67 kDa [5, 6] . However, analysis of the cDNA predicts that the mature LCAT protein contains 416 amino acids with a protein molecular mass of 46917 kDa and the carbohydrate content is estimated to be approx. 25 % of total LCAT mass [5, 7, 8] . The structural and functional regions of the enzyme have been predicted from analysis of the human LCAT primary amino acid sequence and peptide alignment [8] . As a result of a search for homologies with some serine-type hydrolases, Fielding [6] has proposed that an Asp-His-Ser triad is involved in the deacylation of phospholipid substrate, formation of a Ser-O-acyl intermediate, and subsequent transfer of the acyl chain to cholesterol. Recently, Serl81 in the LCAT sequence has been identified as an essential residue for the catalytic function [9] .
There are four potential glycosylation sites at Asn20, Asn84, Asn272 and Asn384 [5] each conforming to the consensus sequence (Asn-X-Ser/Thr) for N-linked glycosylation, where X can be any amino acid except proline [10] . Such N-linked glycosylation is a common post-translation modification in mammalian proteins but the role of the carbohydrate residues in LCAT function significantly different from the wild-type; however, the magnitude and direction of the change depended on the glycosylation site mutagenized. Loss of carbohydrate at position 20, 84 or 272 resulted in a decrease in the specific activity of the mutant enzymes by 18 %, 82% and 62% respectively. In contrast, the mutant protein without glycosylation at position 384 displayed a 2-fold increase in enzyme activity. In addition, a quadruple mutant was constructed such that all four potential glycosylation sites were eliminated. The amount of the unglycosylated LCAT secreted into the culture medium was less than 10 % of the wildtype level and the specific activity of this enzyme was decreased to 
Determination of LCAT concentration
The amount of LCAT protein secreted into the culture medium was determined by solid-phase immunoassay as described previously [12] . The LCAT concentration measured was proportional to absorbance up to 80 ng of LCAT protein.
Determination of LCAT activity
The enzyme activities of wild-type and mutant LCAT gene products were determined using [3H]cholesterol-phosphatidylcholine-apo A-I proteoliposome substrate (exogenous substrate) as previously described [12, 15] . Apo A-I was purified from human plasma by chromatofocusing chromatography [16] . The enzyme activity of the recombinant LCAT was also determined by using [3H]cholesterol-labelled plasma as a source oflipoprotein substrates (endogenous substrate) [12] . For this assay, blood was collected from normal volunteers after 12 h fasting and plasma was prepared by low-speed centrifugation (1200 g, 20 min). The plasma was heat-inactivated at 56°C for 30 min to eliminate endogenous LCAT activity [12, 17, 18] . The concentration of unesterified cholesterol in plasma was determined enzymically by a reagent kit (Boehringer-Mannheim). The endogenous lipoproteins present in the plasma were radiolabelled by equilibration with [3H]cholesterol at 4°C as described by Dobiasova and Schutzova [19] . The labelled plasma was incubated with recombinant LCAT and the rate of [3H]cholesterol esterification in plasma was determined as previously described [12] . to each of these positions, resulting in an apparent decrease in size for all mutant proteins.
Immunoprecipitation of the cell lysate of COS cells transfected with wild-type LCAT cDNA revealed a protein band with a lower molecular mass (57 kDa) than the mature LCAT secreted by COS cells (Figure 2) . A specific band of immunoprecipitable protein was also observed within the cells expressing mutant proteins. As shown in Figure 2 , a protein band with an apparent molecular mass of about 54 kDa was observed in the cells expressing N20Q and N84Q mutant LCAT, whereas a band with a molecular mass of about 52 kDa was seen in the cells expressing the N272Q and N384Q mutant proteins.
Radiolabelling and immunoprecipitation were also performed on the COS cells expressing a quadruple mutant (results not shown). Only after a prolonged exposure of the gels to X-ray film (2 weeks) could a protein band with an apparent molecular mass of 47 kDa be detected. The size of this immunoprecipitable protein was comparable with that of unglycosylated LCAT [5] . Similarly, an immunoprecipitable protein band of equivalent molecular mass (47 kDa) was observed in COS cells transfected with wild-type LCAT cDNA treated with tunicamycin, an inhibitor of N-linked glycosylation (results not shown).
The secreted wild-type enzyme was also partially digested with endoglycosidase F, which cleaves all N-linked carbo- hydrate regardless of complexity by hydrolysing the asparagineoligosaccharide bond. As shown in Figure 3 , on partial digestion, five protein bands were generated with molecular masses between 47 and 66 kDa. It is likely that these protein bands correspond to LCAT with four, three, two, one and no carbohydrate side chains.
To quantify LCAT in the culture medium, we determined the mass of the secreted LCAT protein using polyclonal antibodies specific for human LCAT. As shown in Table 1 , after a 48 h incubation in serum-free medium, the transfected COS cells secreted an average 0.18 gg/ml LCAT for wild-type, 0.16 ,ug/ml for N20Q, 0.16 jtg/ml for N84Q, 0.16 ,g/ml for N272Q, 0.18 /sg/ml for N384Q and 0.02 ug/ml for both quadruple mutant (NQ) and unglycosylated LCAT after tunicamycin treatment.
Functional analysis of secreted mutant LCAT Our next objective was to assess the role ofN-linked glycosylation at each individual N-glycosylation site in LCAT activity. The enzyme activities of the secreted mutant LCAT proteins were determined with a proteoliposome containing [3H]cholesterol, egg phosphatidylcholine and apo A-I. Compared with the wildtype enzyme, a single mutation at position 20, 84 or 272 resulted in a decrease in specific enzyme activity ( Table 1) . Removal of a glycosylation site at position 20 had a mild inhibitory effect on LCAT activity (820% of wild-type activity), whereas the same substitution at position 272 caused a 62 % reduction in enzyme activity. When the mutation occurred at position 84, the enzyme activity was only 18 % of wild-type level. Interestingly, a mutation at position 384 produced more than a 2-fold increase in enzyme activity. The activity of unglycosylated LCAT in the culture medium was only 5 % of that of the wild-type enzyme (Table 1) .
Apo A-I has been shown to be the primary protein activator of LCAT [3, 4] . In this study, we investigated the activation of mutant LCAT by this apolipoprotein. In the absence of apo A-I, no enzyme activity was detected with wild-type, unglycosylated or mutant LCAT proteins (Figure 4 ). When the activity was determined as a function of apo A-I concentration, the mutant enzymes were activated by apo A-I to different extents (Figure 4) . Nevertheless, similar saturation curves were obtained with all mutants carrying a single mutation as well as the wild-type LCAT.
The ability of mutant LCAT to esterify cholesterol in human plasma in vitro was also examined. Various amounts of radiolabelled heat-inactivated plasma were incubated with the culture medium containing either wild-type or mutant LCAT for 5 h at 37 'C. We have previously shown that esterification of cholesterol occurs in a linear manner up to 6 h of incubation under the conditions described [12] . The activities of wild-type and mutant enzymes N20Q, N272Q and N384Q increased in a substrate-dependent manner ( Figure 5 ). However, very low activity was detected in the reactions catalysed by either the N84Q mutant or the quadruple mutant ( Figure 5) . The mechanism by which the mutation at position 20, 272 and 384 altered enzyme activity was examined by kinetic analysis of the data obtained from Figure 5 . The data obtained from the Lineweaver-Burk plot of cholesteryl ester formation versus plasma cholesterol are summarized in Table 2 25 % of the molecular mass of human plasma LCAT [5, 8] . It has been demonstrated that on N-Glycanase treatment, the molecular mass of plasma LCAT is reduced to 47 kDa, which suggests that LCAT contains a large amount of N-linked oligosaccharide moiety, with little, if any, 0-linked carbohydrate [11] . On the basis of the consensus sequence (Asn-X-Ser/Thr), four potential sites for N-linked glycosylation have been predicted in the LCAT sequenced at Asn 0, Asn84, Asn272 and Asn384 [8] . Although the sequence Asn-X-Ser/Thr has been shown to be necessary for N-glycosylation, it does not always result in glycosylation [20] . In order to obtain information on which of the four potential N-glycosylation sites in LCAT were utilized, we performed site-directed mutagenesis to eliminate each of the four sites. We secreted by transfected COS cells. As the molecular mass of the recombinant LCAT studied here is similar to the LCAT protein purified from human plasma, we speculate that all potential glycosylation sites are also used during the synthesis and secretion of native LCAT by hepatocytes in vivo.
A band of immunoprecipitable LCAT was also observed in the cell lysates of the transfected COS cells. However, the molecular mass was lower by approx. 4-5 kDa when compared with the secreted form of LCAT. As only a single intracellular band was observed, it seems likely that this form of LCAT represents the substrate for a rate-limiting step in LCAT processing by COS cells. Moreover, as a similar increase in molecular mass was observed for all LCAT species studied, it appears that this slow step in LCAT transport and secretion was not affected by the absence of glycosylation at any of the four sites. However, the mechanisms associated with the accumulation of intracellular LCAT and its further processing before secretion cannot be addressed by the present study.
Our primary objective in this study was to examine the role of N-glycosylation in the biological function of LCAT. There was no significant change in the secretion rate of the mutant proteins carrying a single mutation from transiently transfected COS cells. However, the absence of N-glycosylation at each site had diverse effects on the activity of LCAT for proteoliposome substrates. For example, the loss of the N-linked glycosylation site at position 84 produced a mutant LCAT with substantially decreased enzyme activity (18 % of the wild-type enzyme). The LCAT proteins containing a mutation at position 20 or 272 also displayed lower enzyme activity. This result indicates that glycosylation at Asn84 may have an important role in the catalytic activity of LCAT or the interaction of the enzyme with substrates. Interestingly, the absence of glycosylation at position 384 resulted in a 2-fold increase in the enzyme activity. This result suggests that the carbohydrate group at position 384 has an inhibitory effect on LCAT activity possibly by sterically hindering access of the substrate to the active site. In contrast, the secretion and catalytic activity of the quadruple mutant was reduced by approx.
900%. Such a decrease might reflect the requirement of the correct conformation of LCAT protein for efficient secretion by COS cells as well as enzyme activity. Alternatively, loss of Nlinked glycosylation might change the secondary structure of the LCAT protein so that the improperly folded unglycosylated enzyme might be degraded more rapidly within the cells. As caution should be exercised when interpreting results obtained from site-directed mutagenesis, we also examined the secretion and activity of unglycosylated LCAT synthesized by transfected COS cells in the presence of tunicamycin, an inhibitor of Nlinked glycosylation [21] . The unglycosylated protein exhibited similar properties to those of the quadruple mutant.
As apo A-I is a cofactor for the LCAT reaction, the mechanism by which apo A-I activates this enzyme has been extensively studied [3, 4, 22] . In the present study, we examined the effect of changes in N-glycosylation of LCAT on its activation by apo A-I. In agreement with the results obtained with the plasma enzyme, the wild-type recombinant LCAT was activated by apo A-I in a dose-dependent manner. The activation by apo A-I was also observed in the reaction catalysed by the mutant enzymes carrying a mutation at one of the four N-glycosylation sites. These results suggest that the removal of some of the N-linked carbohydrate groups does not affect LCAT activation by apo A-I.
We have also examined the ability of mutant LCAT to esterify cholesterol in human plasma. We found that partial or complete loss of N-glycosylation had a profound effect on LCAT activity towards plasma substrates. Changes in the consensus sequence at all four N-glycosylation sites completely abolished the ability of the enzyme to utilize substrates in the plasma. The apparent Vmax/Km ratios have been used by a number of investigators to study the kinetics of the LCAT reaction [23] [24] [25] . In the present study, this parameter was decreased for the mutants carrying a substitution (Asn to Gln) at position 20 or 272. These results suggest that the efficiency with which these two mutant enzymes utilized substrates in the plasma was reduced. Kinetic analysis also revealed that the increased activity associated with the N384Q mutant enzyme was not a result of an enhanced affinity of the enzyme for the substrate, but was due to more efficient utilization of the substrate, as the ratio Vm,, /Km was about twice as high as that of the wild-type enzyme. This suggests that the oligosaccharide at position 384 has an inhibitory effect on LCAT activity, but the exact mechanism remains unclear. The N84Q mutant exhibited lower reactivity with plasma substrates, and the quadruple mutant completely lost the ability to utilize substrates in the plasma.
In summary, the present study has demonstrated that all four N-glycosylation sites of LCAT are utilized: two are in the Nterminal region (Asn20 and Asn84) and two are in the C-terminal region (Asn272 and Asn384). Glycosylation of all four sites is required to generate the full-size mature LCAT protein. Although complete N-linked glycosylation does not appear to be required for LCAT secretion, the pattern of glycosylation has a profound effect on the catalytic activity of the enzyme.
